Skip to Content
Merck
All Photos(1)

Documents

Safety Information

D-085

Supelco

Dexamethasone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H29FO5
CAS Number:
Molecular Weight:
392.46
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

InChI key

UREBDLICKHMUKA-CXSFZGCWSA-N

Gene Information

human ... NR3C1(2908)

General description

Dexamethasone is a potent glucocorticoid which acts as an anti-inflammatory and immunosuppressant for therapeutic treatments in many inflammatory and autoimmune conditions, oncology, and endocrine diseases such as Addison′s disease. Dexamethasone levels in serum or plasma are measured by LC-MS/MS for dexamethsaone suppression tests or monitoring dexamethsaone treatment regimens. This Certified Spiking Solution® is suitable for use as starting materials in the preparation of calibrators and controls for dexamethasone testing methods by LC-MS/MS.

Application

  • Controlled drug delivery systems: Hydrogel microneedles incorporating dexamethasone demonstrate a programmed mesophase transition, optimizing the controlled release of drugs for therapeutic applications. This advancement in drug delivery technology illustrates the utility of dexamethasone solution in developing innovative pharmaceutical materials (Dawud et al., 2024).
  • Enhanced nasal drug administration: Bovine Serum Albumin nanoparticles, integrated with dexamethasone, highlight a novel gelling system designed to enhance nasal drug delivery. This research underscores the potential of dexamethasone solution in creating more effective and patient-friendly drug delivery modalities (Mardikasari et al., 2023).
  • Sustained-release formulations: The development of polyvinyl alcohol microparticles for the sustained release of dexamethasone via a coaxial microfluidic system demonstrates the critical role of dexamethasone solution in producing precision drug delivery systems that improve therapeutic efficacy and patient compliance (Abdi Majareh et al., 2023).
  • Topical drug delivery for ocular conditions: Dexamethasone-loaded chitosan nanoparticles were developed for topical application in a rabbit model of endotoxin-induced uveitis, indicating significant advancements in localized drug delivery systems using dexamethasone solutions. This application is particularly relevant in treating inflammatory eye diseases with enhanced drug delivery efficiency (Alkholief et al., 2023).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Group 4: Flammable liquids
Alcohols
Hazardous rank II

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

D-085-CC:
D-085-1ML:4548173315157
D-085-CHK:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

María-Victoria Mateos et al.
The New England journal of medicine, 369(5), 438-447 (2013-08-02)
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. In this randomized, open-label, phase 3 trial, we randomly assigned 119
Shankar Swaminathan et al.
Journal of biomedical nanotechnology, 9(6), 998-1007 (2013-07-19)
Nanosponges (NS) were synthesized by crosslinking of beta cyclodextrins with diphenyl carbonate. It is a hyper-branched polymer with an ultra high encapsulation efficiency leading to formation of colloidal systems. Dexamethasone (DEX) on the other hand is a poorly soluble drug
Fausto Roila et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(2), 101-106 (2013-12-11)
A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer. The aim of this study was to verify
Erich Piovan et al.
Cancer cell, 24(6), 766-776 (2013-12-03)
Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically
Peter Bärtsch et al.
The New England journal of medicine, 368(24), 2294-2302 (2013-06-14)
A 45-year-old healthy man wishes to climb Mount Kilimanjaro (5895 m) in a 5-day period, starting at 1800 m. The results of a recent exercise stress test were normal; he runs 10 km 4 or 5 times per week and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service